Objectives: We aimed to assess the prognostic ability of the ST score, DAPT score, and PARIS score in a Chinese population.
| I N TR ODU C TI ON
Dual-antiplatelet therapy (DAPT) with aspirin plus a P2Y 12 inhibitor reduces thrombotic complications, but increases bleeding complication, after percutaneous coronary intervention (PCI) [1] . Albeit without a universally recognized tool, current guidelines support weighting longterm risk for both coronary thrombotic and bleeding events before the selection of DAPT duration [2] .
Most ischemic and bleeding risk models after PCI thus far have focused on in-hospital or short-term risk, and those focused on long- The last decade has witnessed an exponential increase in PCI use in China, with approximately 450,000 PCI cases performed in 2013 [6, 7] . Given the increasing number of patients with acute coronary syndrome (ACS), we aimed to assess the prognostic ability of the ST score, DAPT score and PARIS score in a Chinese ACS cohort after drug eluting stent (DES) implantation.
| M ET HOD S

| Patient population
Data from consecutive ACS patients undergoing emergent or elective PCI at a single institution (Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China) were retrospectively collected from January 1 to December 31, 2013. As shown in Figure 1 , after excluding 337 patients (300 without stent implantation, 31 who received bare metal stents, and 111 with a failed procedure), the remaining 6,088 patients undergoing successful DES implantation constituted the final FIG URE 1 Flow chart of patients included in the analysis. According to the derivation population of risk scores, ST score was validated based on the overall population. PARIS score validation cohort was limited to patients not experiencing myocardial infarction, stent thrombosis, or major bleeding in-hospital or within the first 12 months. DAPT score validation cohort was limited to only patients not experiencing myocardial infarction, stent thrombosis, or major bleeding within the first 12 months. Coronary thrombotic events were defined as the occurrence of definite or probable stent thrombosis or myocardial infarction. PCI, percutaneous coronary intervention; CTE, coronary thrombotic events study cohort. Two-year follow-up was completed in 99.5% of the patients. As the derivation cohort of the PARIS Score excluded patients experiencing in-hospital events, the validation cohort in this study accordingly excluded patients experiencing in-hospital death, ST or myocardial infarction (MI), and MB events, with 5,973 patients remaining. Those experiencing death, ST or MI, and MB events within 1 year were also excluded to compare the prognostic capability of the DAPT score and PARIS score for 1-to 2-year outcomes; meanwhile, for DAPT score validation, patients who discontinued DAPT within 1 year were also excluded. Details of ACS diagnosis are shown in the Supporting Information, Appendix. 
| Risk score models
Supporting Information, Table 1 presents the characteristics of the three risk score models [3] [4] [5] . Briefly, the ST score was developed in 2012 to predict 1-year risk of definite or probable ST. The DAPT score and PARIS score were developed in 2016 to predict risks for both ischemia and bleeding 12-30 months and 2 years after PCI, respectively.
| Study definitions and outcomes
The primary ischemic outcomes were 2-year definite or probable ST and CTE (defined as a composite of definite or probable ST or MI), and the primary bleeding outcome was 2-year MB. The secondary outcomes included ischemic major adverse cardiovascular events (MACE, a composite of all-cause death, MI, and definite or probable ST), major adverse cardiac and cerebral events (MACCE, a composite of all-cause death, MI, ischemic stroke, and definite or probable ST) and any clinically relevant bleeding events (defined as the occurrence of a BARC type 2, 3, or 5 bleed). Specific definitions for outcome components are listed in the Supporting Information, Appendix. The ST score, DAPT score, and PARIS score were calculated for every patient using established definitions of the different risk factors as previously described [3] [4] [5] . The distribution for each risk score was visualized graphically and compared with respective to the derivation cohort. Model discrimination was assessed by calculating the area under the receiver-operating characteristic (ROC) curve and expressed as the c-statistic with 95% CI. The Hosmer-Lemeshow test for calibration was also performed whenever a c-statistic was calculated. Discrimination for risk scores was compared when necessary.
| Statistical analysis
All tests of statistical significance were two-tailed, and P-values of <0.05 were considered to indicate statistical significance. All analyses were performed using IBM SPSS Statistics version 21.0 (SPSS, Inc., Chicago, IL).
| RE S U L TS
| Baseline characteristics
The baseline clinical, angiographic, and procedural characteristics in the overall patient population and subsets thereof, with versus without 2-year CTE or MB, are summarized in Supporting Information, Tables 2   and 3 .
Among the 6,088 consecutive ACS patients undergoing DES implantation, the mean age was 58.3 years, and 23.1% were women;
77.6% presented with NSTE-ACS and 22.4% presented with STEMI;
and 5.1% (n 5 312) underwent emergent PCI and 94.9% underwent elective or early PCI.
Patients developing CTE were significantly older, more frequently female, more likely to have a family history of premature coronary artery disease, previous MI or PCI, anemia, and impaired renal function, presented more often with STEMI and underwent more emergent procedures compared to patients without CTE. In addition, patients with CTE also displayed important differences regarding angiographic and procedural characteristics compared to those free of CTE, which included a smaller minimal luminal diameter before the procedure, a higher prevalence of complex target lesions (including in-stent restenosis, thrombus-containing lesion, bifurcation lesion, chronic total occlusion lesion, as well as baseline TIMI flow grade 0/1), aspiration catheter used, implantation of IABP, a lower frequency of post-dilatation balloon used, and lower maximum balloon pressure.
Patients experiencing MB were more likely to be older, have had a previous stroke, receive an emergent procedure, undergo implantation
of IABP, and receive warfarin at discharge compared to those without MB.
| Two-year ischemic and bleeding outcomes
As shown in Table 1 , 2.62% of the patients experienced CTE at the 2-year follow-up, including 0.61% with definite or probable ST and 2.51% with MI. Over 2 years, the rate of death from any cause was 1.16%, including 0.64% cardiac deaths. In addition, 1.45% of patients experienced stroke including 1.25% ischemic stroke and 0.20% hemorrhagic stroke. The cumulative incidence of 2-year ischemic MACE and MACCE was 3.45% and 6.65%, respectively.
At 2-year follow-up, 0.50% of patients experienced MB, and 2.53% experienced clinically relevant bleeding events. The incidence of adverse events was lower in our cohort than that in risk score derivation cohorts, as well as previous reports from large registries and randomized trials [3] [4] [5] 8, 9] . We can suggest several potential reasons for the markedly lower rate of ischemic outcomes, especially ST, in the present registry. First, there might be ethnic differences in the propensity for thrombosis. An increasing body of data suggests that East Asian patients have different risk profiles for thrombophilia compared with white patients [10] . The incidence of ST about 10 years ago reported in South Korean and Japanese registries (0.2% per year) was significantly lower than that in Western registries (0.6% per year) after first-generation DES implantation [10] . Recently, the ABSORB China Trial also reported a lower rate of cumulative 1-year stent and scaffold thrombosis than the ABSORB II trial conducted in Western populations (0.2% vs. 0.6%) [11, 12] . Differences in genetic polymorphisms and levels of hemostatic factors, endothelial markers, and inflammatory markers between ethnicities might partially account for the underlying mechanism. Second, the rate of DAPT discontinuation within the first 12 months was significantly lower in our cohort than in previous studies with only 0.82% within 30 days, 1.40% within 6 months, and 3.88% through 12 months (Supporting Information, Figure 1 ). Well-established evidence has indicated that the early discontinuation of antiplatelet therapy, especially thienopyridine, was an important modifier of ischemic risk during the follow-up period. Third, ischemic recurrences after stenting have dropped considerably in recent years because of the introduction of novel stent technologies and progressive refinement of pharmaco-interventional techniques and strategies. Conversely, the lower incidence of MB in our cohort may be due to cautious clinical evaluation, and lower-dose aspirin (75-100 mg daily) compared to the historic, standard-dose aspirin (162-325 mg), as well as the fact that more potent P2Y 12 inhibitors, such as prasugrel and ticagrelor, had not been used to date at our institution in 2013.
| Validation of risk score models
Additionally, it is noted that a considerable number of patients in our cohort were transferred from other hospitals a few days after the heart attack; thus, several adverse events might have already occurred before admission.
The unsatisfactory predictive ability of the three risk scores in our cohort might be secondary to several causes. First, the key factor was the variations in event rates and ethnic discrepancies we mentioned above. Second, there might be other differences in study population characteristics. Compared to the derivation cohorts, the patients in our cohort were slightly younger and were more likely to be male and have a lower frequency of previous MI and revascularization and peripheral arterial disease. In addition, our ACS cohort was mainly composed of unstable angina, and the majority underwent a non-emergent procedure, whereas the ACS cohort of ST score was primarily composed of acute MI undergoing emergent or early PCI. These differences suggest that our cohort might have a lower risk profile compared with the ST score derivation cohort. However, in contrast to our ACS cohort, the derivation cohorts of DAPT score and PARIS score included over 50%
non-ACS patients (Supporting Information, Table 5 ). Third, the stent types used were different among our cohort and three model derivation cohorts. Bare mental stent (BMS) and first-generation DES were used in the whole ST score cohort (mostly paclitaxel-eluting stent) and 48.8% of the DAPT score cohort, whereas newer-generation DES was primarily used in our cohort and the PARIS score cohort (Supporting Information, Table 5 ). Theoretically, newer-generation stents have an improved safety profile (i.e., lower risk of ST) compared with firstgeneration stents. Recent evidence indeed has suggested lower frequency of ST with a widely studied second-generation DES. However, no major difference in ST has been observed among different types of stents used in many studies [13] . Analogously, the choice of DES types did not influence the long-term risk of CTE in this study. Fourth, the P2Y 12 inhibitor used was different among our cohort and three model derivation cohorts. As is well-known, choice of antiplatelet therapy, especially the P2Y 12 inhibitor, is an important modifier of ischemic and bleeding risk after DES implantation [14, 15] . Clopidogrel and ticlopidine were used in the whole ST score derivation cohort, and clopidogrel was the only thienopyridine agent used in our cohort, whereas the more potent P2Y 12 inhibitor prasugrel was used in 6.26% and 31.6% of the PARIS score and DAPT score derivation cohorts, respectively (Supporting Information, Table 5 ). As shown in Supporting Information, Figure 2, most patients with CTE discontinued DAPT before or at 1 year.
Conversely, patients presented with MB events more frequently with prolonged duration of DAPT, especially in those with lower bleeding risk at baseline. Since all risk scores did not include DAPT utilization in the models, which might have weakened the power to assess the risk models.
Given that Western-derived risk models are limited in their transferability and applicability to our cohort, new risk models need to be built exclusively on Chinese populations. In this study, we also identified abnormal baseline platelet counts and previous strokes as independent predictors of long-term bleeding, while neither had been incorporated into the existing risk models.
Current guidelines recommend 12 months of DAPT after ACS but also suggest leaving ample room for shortening or extending the duration of DAPT based on the individual's risks of ischemia and bleeding Abnormal baseline platelet count was defined as baseline platelet count <100 or >300*10 9 /L.
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| 579 [2, 16, 17] . Recently, accumulating data support extended DAPT beyond 1 year after ACS, especially for patients with MI [1, 18, 19] . Our analysis also indicated that the DAPT beyond 1-year group had significantly lower rates of all-cause death and cardiac death compared with the DAPT 1-year group, while the bleeding risk between the two groups was similar (Supporting Information, Figure 3 ). Of note, we could not accurately assess the impact of DAPT duration on long-term ischemic and bleeding outcomes because of the nonrandomized design. Given the huge economic burden with extended DAPT and the increasing use of more potent P2Y 12 inhibitor ticagrelor in ACS in China, the optimal duration and intensity of DAPT should be further defined by prospective randomized trials evaluating the net clinical benefit.
Furthermore, investigators designing future clinical trials should plan for appropriate data collection that will facilitate construction of predictive models and include such approaches in their primary statistical analysis plans. For example, in a new risk model for the prediction of out-of-hospital bleeding during DAPT, previous bleeding emerged as the strongest predictor of bleeding [20] , whereas the information on this variable was unavailable in most studies.
| L I M I TA TI ONS
Several limitations need to be kept in mind when interpreting the results of this study. First, this study carries the well-known limitation of the retrospective design; thus, a portion of information on patient and treatment characteristics was unavailable. Nevertheless, our database included all of the variables that are used to calculate the three risk scores. Moreover, this study had high follow-up rates, independent endpoint adjudication, and other quality-control methods that mirror those observed in high-quality trials. A further limitation of the study is its single-center nature, as the management of patients is relatively homogeneous, which reduces the generalizability of our findings to populations with different therapeutic management patterns. Fu Wai Hospital is the largest cardiovascular center (>10,000 PCIs/year, and >400 primary PCIs/year) in China, and many patients in our cohort were transferred from other hospitals even several days after a heart attack for various reasons, such as complex or high-risk angiographic findings, precluding the chance for emergent or early PCI. Therefore, our cohort indeed included ACS with various time frames and different clinical and angiographic features seen in the "real world." Finally, because our study exclusively enrolled patients with ACS, the validity of these risk scores for other patients should be further examined in future studies.
| C ONC LUSI ON S
Among contemporary coronary thrombosis and bleeding risk scores, only DAPT score was determined to be a modestly accurate quantitative tool for later MB prediction in ACS patients after DES implantation in China. Therefore, the three risk scores derived and initially validated in Western populations may not be applicable to a Chinese population,
and new risk models need to be designed exclusively for Chinese populations.
